78 related articles for article (PubMed ID: 7873994)
1. Prognostic factors in myeloma: what they tell us about the pathophysiology of the disease.
Joshua DE; Brown RD; Gibson J
Leuk Lymphoma; 1994 Nov; 15(5-6):375-81. PubMed ID: 7873994
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in multiple myeloma.
Kyle RA
Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of the escape phase of myeloma.
Joshua DE; Gibson J; Brown RD
Blood Rev; 1994 Mar; 8(1):13-20. PubMed ID: 8205006
[TBL] [Abstract][Full Text] [Related]
4. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
5. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
Gadó K; Domján G; Hegyesi H; Falus A
Cell Biol Int; 2000; 24(4):195-209. PubMed ID: 10816321
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.
Shiao RT; McLeskey SB; Khera SY; Wolfson A; Freter CE
Leuk Lymphoma; 1996 Apr; 21(3-4):293-303. PubMed ID: 8726410
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic factors in multiple myeloma. Review of the literature].
Bauduer F; Troussard X; Delmer A
Bull Cancer; 1993 Dec; 80(12):1035-42. PubMed ID: 8081040
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
[TBL] [Abstract][Full Text] [Related]
9. Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies.
Boccadoro M; Durie BG; Frutiger Y; Gavarotti P; Redoglia V; Massaia M; D'Alberto M; Marmont F; Gallamini A; Tribalto M
Acta Haematol; 1987; 78(4):239-42. PubMed ID: 3122489
[TBL] [Abstract][Full Text] [Related]
10. Plasma cell myeloma--new biological insights and advances in therapy.
Barlogie B; Epstein J; Selvanayagam P; Alexanian R
Blood; 1989 Mar; 73(4):865-79. PubMed ID: 2465790
[TBL] [Abstract][Full Text] [Related]
11. [The wide variations of the clinical behavior and prognosis in multiple myeloma].
Kanoh T; Hirashimizu K
Rinsho Ketsueki; 1993 Apr; 34(4):439-43. PubMed ID: 8510330
[TBL] [Abstract][Full Text] [Related]
12. Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.
Pappa CA; Alexandrakis MG; Boula A; Psarakis FE; Kolovou A; Bantouna V; Stavroulaki E; Tsirakis G
Hematol Oncol; 2013 Dec; 31(4):201-5. PubMed ID: 23576184
[TBL] [Abstract][Full Text] [Related]
13. Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.
Villunger A; Egle A; Kos M; Hittmair A; Maly K; Greil R
Int J Cancer; 1996 Feb; 65(4):498-505. PubMed ID: 8621234
[TBL] [Abstract][Full Text] [Related]
14. Why better prognostic factors for multiple myeloma are needed.
Kyle RA
Blood; 1994 Apr; 83(7):1713-6. PubMed ID: 8142638
[No Abstract] [Full Text] [Related]
15. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
16. Role of interleukin 16 in multiple myeloma.
Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
[TBL] [Abstract][Full Text] [Related]
17. [Multiple myeloma. Mechanisms of proliferation and neoplastic progression and their clinical implications].
Boccadoro M; Battaglio S; Dianzani U; Frieri R; Gallone G; Massaia M; Omedè P; Palumbo A; Pileri A
Haematologica; 1991 Jun; 76 Suppl 3():100-6. PubMed ID: 1752506
[No Abstract] [Full Text] [Related]
18. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.
Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G
Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961
[TBL] [Abstract][Full Text] [Related]
20. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
Gaillard JP; Liautard J; Klein B; Brochier J
Eur J Immunol; 1997 Dec; 27(12):3332-40. PubMed ID: 9464821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
